Eyenovia (NSDQ:EYEN) said today that it enrolled the first patient in the first of two Phase III trials of the company’s MicroStat program.
The Mist-1 and Mist-2 trials are slated to study the safety and efficacy of the company’s 2.5% phenylephrine, 1% tropicamide eye solution, delivered as a micro-dose using the Optejet device.
Get the full story at our sister site, Drug Delivery Business News.
The post Eyenovia launches Ph3 trial for pupil dilation tech appeared first on MassDevice.